Close Menu

BioMérieux

The platform received 510(k) clearance from the US Food and Drug Administration for the expanded identification of mycobacteria, Nocardia, and molds.

The Inhale project is assessing respiratory disease tests on Oxford Nanopore's MinIon and PCR platforms from Curetis and BioMérieux's BioFire Diagnostics.

BioMérieux's organic growth saw a 9 percent increase to €566.4 million from €512.3 million in Q2 2016.

The firm will encounter stiff competition, particularly from BioMérieux and Luminex, but there are untapped opportunities for adoption, according to industry analysts.

BioMérieux said that the FilmArray RP2 reduces sample-to-result time to 45 minutes from about one hour, and provides increased pathogen coverage and sensitivity.

The firm has dedicated the facility to the development of FilmArray, its PCR-based multiplex system for the syndromic diagnosis of infectious diseases.

The approach is based on a new approval of the BacT/ALERT Virtuo system and new indications for the firm's procalcitonin assay.

The firm also announced a CE mark and pending commercial release for a FilmArray Respiratory Panel test for 22 pathogens responsible for respiratory tract infections. 

Applied Biocode intends to have panel for identifying 18 gastrointestinal pathogens on the clinical market by the end of the year.

The fully-automated system features technology to measure blood volumes in each culture bottle to ensure compliance with accreditation guidelines.

Pages